Trump Administration Accelerates Psychedelic Research via Executive Order and FDA Fast-Track Reviews
Introduction
The Trump administration has issued an executive order to increase access to psychedelic drugs for serious mental health problems. The Food and Drug Administration (FDA) has also given priority review vouchers for three experimental psychedelic drugs. These actions show a coordinated effort by the federal government to speed up research and regulatory processes for substances that are still illegal under federal law.
Main Body
The executive order, signed by President Donald Trump, directs federal agencies—including the Department of Veterans Affairs—to work together on data sharing, increase clinical trial participation, and speed up the process of rescheduling any psychedelic that receives FDA approval. Legal experts have noted that while the order's specific rules may not have a strong legal impact, its symbolic meaning is important. Mason Marks, a law professor at Florida State University, observed that the president's public support for the order, including a press conference with podcaster Joe Rogan and former Navy SEAL Marcus Luttrell, is uncommon and could help more people accept psychedelic research. In a parallel development, the FDA announced it has issued priority review vouchers for two psilocybin programs targeting treatment-resistant depression and one methylone program for post-traumatic stress disorder. These vouchers allow regulators to shorten review times from months to weeks, although they do not mean the drugs will be approved. The FDA also allowed early testing in the U.S. of noribogaine, a derivative of the psychedelic ibogaine, for alcohol use disorder—marking the first time such a compound has been approved for clinical study in the country. Commissioner Marty Makary stated that the agency has a responsibility to study these possible treatments quickly, while emphasizing that they remain experimental and require strong evidence. The administration's actions reflect growing political support for psychedelics among veterans' groups, conservative influencers, and members of the Make America Healthy Again movement led by Health Secretary Robert F. Kennedy Jr. Joe Rogan, who attended the Oval Office event, claimed he texted President Trump about ibogaine, to which the president reportedly responded positively. Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, noted that the order shows which groups are influencing the administration, particularly a medical approach focused on veterans rather than a broader approach based on rights. She cautioned that without continued investments in healthcare access and community-based treatment, the advantages of changing the law may be small. At the same time, the Justice Department has partly delivered on a separate executive order to reschedule cannabis. Acting Attorney General Todd Blanche announced that FDA-approved and state-licensed medical marijuana will be moved from Schedule I to Schedule III, and a hearing is scheduled for June to consider reclassifying recreational cannabis. Experts pointed to institutional resistance from the Drug Enforcement Administration as a factor that has delayed rescheduling. Marks noted that the psychedelic order may face fewer obstacles because the FDA is already open to approving such drugs, with potential approvals expected within one to three years. Several experts have expressed caution about the accelerated review process. Marks raised concerns that the order's directive to use artificial intelligence in safety reviews could lead to missed adverse events, potentially resulting in drug recalls. Packer emphasized that faster review must be paired with strong evidence, strong patient protections, and a broader public-health approach, noting that psychedelics are not a cure-all. Dr. Peg Nopoulos, chair of the University of Iowa's psychiatry department, welcomed the increased research focus but stressed that the science behind any approval must be "rock solid" to understand benefits, risks, and appropriate patient populations.
Conclusion
The Trump administration's executive order and the FDA's fast-track reviews show a major change in federal policy toward psychedelic medicines, supported by political support from veterans, influencers, and health advocates. However, experts emphasize that the success of these initiatives will depend on careful scientific testing, close oversight of accelerated processes, and additional investments in public health infrastructure.